Associations - EGFR S768I

EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: C2 – Inclusion Criteria Front Pharmacol - 3 weeks (New C2)	dacomitinib Sensitive: C2 – Inclusion Criteria Front Pharmacol - 3 weeks - (New C3)
EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: B - Late Trials	afatinib Sensitive: B - Late Trials
EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C2 – Inclusion Criteria	osimertinib Sensitive: C2 – Inclusion Criteria
EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	gefitinib Resistant: C3 – Early Trials	gefitinib Resistant: C3 – Early Trials
EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C3 – Early Trials	erlotinib Sensitive: C3 – Early Trials
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	afatinib Resistant: C3 – Early Trials	afatinib Resistant: C3 – Early Trials
EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	EGFR S768I EGFR S768I	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	EGFR S768I EGFR S768I	Lung Adenocarcinoma LUAD	erlotinib Sensitive: C4 – Case Studies	erlotinib Sensitive: C4 – Case Studies